-Case Reports-

Capecitabine Plus Bevacizumab as First-Line Therapy for Patients with Metastatic Colorectal Cancer and Poor Performance Status

Yasufumi Yamada, Kazuhiko Yoshimatsu, Hajime Yokomizo, Sachiyo Okayama, Masaya Satake, Arika Ida, Hiroyuki Maeda and Shunichi Shiozawa

Department of Surgery, Tokyo Women's Medical University, Medical Center East, Tokyo, Japan

Background: The benefit of chemotherapy for patients with metastatic colorectal cancer has not been established.
Methods: We retrospectively evaluated the effectiveness of chemotherapy with capecitabine and bevacizumab for patients with a performance status (PS) of 3.
Results: Seven patients were included; median age was 82 years (range, 65-91 years). Response was not ascertained; however, the disease control rate was 83.3%. Median PFS and OS were 10.0 and 25.8 months, respectively. Hand-foot syndrome was the most common toxicity observed (3 patients; 42.9%). Grade 3 toxicity was observed in 1 patient with proteinuria and 1 with hypertension.
Conclusion: Chemotherapy using capecitabine and bevacizumab appeared to improve OFS and OS for patients with poor PS. However, care must be taken not to impose unnecessary burdens on patients with poor PS.

J Nippon Med Sch 2021; 88: 496-499

Keywords
capecitabine, bevacizumab, metastatic colorectal cancer, performance status

Correspondence to
Yasufumi Yamada, MD, Department of Surgery, Tokyo Women's Medical University, Medical Center East, 2-1-10 Nishiogu, Arakawa-ku, Tokyo 116-8567, Japan
yamadayasu_0129@me.com

Received, June 30, 2020
Accepted, September 11, 2020